The Hemoglobin–Albumin–Lymphocyte–Platelet Score and Diabetic Neuropathy in Patients with Type 2 Diabetes Mellitus
Experimental and Clinical Endocrinology & Diabetes · 2026-10 · 134 (10) · 338-343
DOI: 10.1055/a-2890-1089 ↗Abstract
Abstract Diabetic neuropathy is a common microvascular complication of type 2 diabetes mellitus associated with chronic inflammation and metabolic dysregulation. The hemoglobin–albumin–lymphocyte–platelet score is a composite index reflecting nutritional and inflammatory status, but its association with diabetic neuropathy remains insufficiently characterized. In this retrospective cross-sectional study, 212 patients with type 2 diabetes mellitus were evaluated. Diabetic neuropathy was defined using electrophysiological criteria. Multivariable logistic regression analysis was performed to assess the association between the hemoglobin–albumin–lymphocyte–platelet score and diabetic neuropathy after adjustment for age, sex, diabetes duration, body mass index, and glycated hemoglobin. The hemoglobin–albumin–lymphocyte–platelet score was analyzed as a continuous variable (per 0.1-unit increase) and in quartiles. Receiver operating characteristic curve analysis was used to evaluate model discrimination. Diabetic neuropathy was present in 45.2% of patients. The hemoglobin–albumin–lymphocyte–platelet levels were significantly lower in patients with diabetic neuropathy compared to those without diabetic neuropathy (0.36±0.18 vs. 0.72±0.39, p
EUVIMED